The global stem cell therapy market is experiencing rapid growth and is anticipated to continue expanding at a substantial rate in the coming years. This growth can be attributed to various factors, including the increasing prevalence of chronic diseases and injuries, rising awareness about the therapeutic potential of stem cells, and advancements in stem cell technologies. Additionally, the growing number of stem cell banks and repositories, along with the rising investments in stem cell research, are further propelling market growth. Moreover, the development of novel stem cell-based treatments and therapies for a wide range of medical conditions, including cancer, neurodegenerative disorders, and autoimmune diseases, is driving the market forward.
The Global Stem Cell Therapy Market size was valued at USD 257 million in 2022 and is expected to reach USD 921.12 million by 2030, with a CAGR of 17.3% during the forecast period 2023 to 2030.
To know more, visit https://www.databridgemarketresearch.com/reports/global-stem-cell-therapy-market
Below are the Top Five Stem Cell Therapy Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Osiris Healthcare
|
Osiris Therapeutics, Inc. specializes in the development and commercialization of products in regenerative medicine. They focus on mesenchymal stem cell (MSC) technology for treating various conditions, including orthopedic, cardiovascular, and wound healing applications. Osiris' flagship product, Grafix, is a significant contributor to their market presence.
|
|
North America
|
In March 2019, Osiris Therapeutics Inc and Smith+Nephew expanded the product portfolio of regenerative medicine and wounds and chronic management by the launch of Grafix PL, after the acquisition of Osiris Therapeutics Inc. The expansion resulted in an enhanced product portfolio with strong clinical evidence addressing critical needs in the marketplace. It increased the stem cell market growth.
|
|
2.
|
JCR Pharmaceuticals Co., Ltd.
|
JCR Pharmaceuticals Co., Ltd. is a Japanese biotechnology company that focuses on the development and commercialization of cell and gene therapies, including stem cell-based treatments. They are renowned for their work in regenerative medicine and rare genetic disorders. Their innovative approach to stem cell therapy has positioned them as a key player in the global market.
|
|
North America, Europe, Asia-Pacific
|
In October 2022, JCR Pharmaceuticals Co., Ltd. and Sysmex Corporation announced the establishment of a joint venture focused on the research, development, manufacture, and sale of cell-based regenerative medicine products, including hematopoietic stem cells and other types of stem cells.
|
|
3.
|
Orthofix US LLC.
|
Orthofix US LLC, a global medical device company, is committed to improving patients' lives by providing superior reconstructive and regenerative orthopedic and spine solutions. Their involvement in the stem cell therapy market is primarily through their biologics division, which develops and markets innovative solutions for bone growth and repair.
|
|
North America, Europe, Asia-Pacific
|
In February 2022, Orthofix Medical Inc. announced the expansion of Trinity Elite and Trinity Evolution allografts with viable cells. The expansion would result in an improvement in the biologics product range and an increase in revenue.
|
|
4.
|
MEDIPOST
|
MEDIPOST is a South Korean biotechnology company specializing in stem cell-based therapeutics and regenerative medicine. Known for its flagship product, Cartistem, which treats osteoarthritis, MEDIPOST is at the forefront of developing novel stem cell therapies for a range of medical conditions. Their research and development efforts are shaping the future of biotechnology and stem cell therapy.
|
|
North America, Europe, Asia-Pacific
|
In March 2022, MEDIPOST invested in a contract development and manufacturing company (CDMO) for cell gene therapy products in North America and clinical trials in the U.S., such as stem cell therapy. Cartistem is a stem cell therapeutic procedure for the treatment of degenerative osteoarthritis.
|
|
5.
|
Takeda Pharmaceutical Company Limited
|
Takeda Pharmaceutical Company Limited, a global leader in the pharmaceutical industry, is dedicated to addressing unmet medical needs through innovative therapies. Their involvement in stem cell therapy is part of their broader commitment to regenerative medicine and advanced therapeutics. Takeda's strategic investments and collaborations in stem cell research have reinforced its position in the global market.
|
|
Americas, Europe, Asia
|
In September 2020, Takeda Pharmaceutical Company Limited had received product approval from the Japan Ministry of Health, Labour and Welfare to manufacture and market Alofisel (darvadstrocel), an adipose-derived mesenchymal stem cell for the treatment of complex perianal fistulas in patients with non-active or mildly active luminal Crohn’s disease (CD). The approval received would result in post market approval and product launch. This is expected to increase market growth.
|
Conclusion
The global stem cell therapy market is witnessing significant advancements driven by key players such as Osiris Therapeutics, JCR Pharmaceuticals, Orthofix US LLC, MEDIPOST, and Takeda Pharmaceutical Company Limited. These companies are at the forefront of innovative developments in regenerative medicine, leveraging their expertise in mesenchymal stem cell technology, gene therapy, and orthopedic solutions to address a wide range of medical conditions. With a strong focus on research and development, strategic collaborations, and product commercialization, these industry leaders are poised to shape the future of stem cell therapy, offering promising therapeutic options and driving substantial growth in the market.
